Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Response to therapy higher in clinical trial than real-world RCC patients
Among patients with metastatic renal cell carcinoma (RCC) who have received first-line therapies, complete response rates are lower in the real-world population than in the clinical trial population, reports a recent study. Complete response predicts a favourable overall survival.
SC trastuzumab cost-saving for HER2-positive breast cancer in Hong Kong
A cost minimization analysis based on a literature review and Hong Kong data suggests that using subcutaneous (CS) instead of intravenous (IV) trastuzumab for HER2-positive breast cancer (BC) patients can offer an annual saving of more than USD 8.3 million to the Hong Kong healthcare system.
Frequent aspirin use protects against ovarian cancer even in women with genetic predisposition
Genetic susceptibility to ovarian cancer does not appear to modify the protective association between frequent aspirin use and the risk of developing the cancer, as shown in a study.
Cyclophosphamide-free adjuvant chemo works against ERBB2-negative breast cancer
The adjuvant chemotherapy regimen epirubicin plus paclitaxel (EP) appears to be as good as the regimen that consists of epirubicin and cyclophosphamide followed by paclitaxel (EC-P) in the treatment of Asian women with operable ERBB2-negative breast cancer, according to the results of an open-label phase III trial.